Johnson & Johnson

Johnson & Johnson

JNJ

Get informed when a big investor buys or sells

+ Follow
Market Cap$618.61B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Johnson & JohnsonJohnson & Johnson29.62.04%26%8.70.2

Earnings Call Q2 2026

July 15, 2026 - AI Summary

Strong Q2 performance; guidance raised (core “good” takeaway) - Q2 worldwide sales: $25.3B, +5.6% operational (reported growth pressured by ~460 bps STELARA headwind). - Adjusted EPS $2.90 (+5.7% adjusted net earnings; EPS +4.7% YOY). - Management emphasized a pipeline/portfolio strength: 28 products/platforms each > $1B annual sales and operational growth across Innovative Medicine.
2026 outlook improved: operational sales growth +$400M (expect faster H2 growth) - Company raised 2026 operational sales growth to 6.5%–7.1% (midpoint $100.6B), reflecting stronger 2H performance from new launches (e.g., ICOTYDE/INLEXZO/TREMFYA). - Reported sales growth now 7.0%–7.6% (mid $101.1B, +7.3%) with estimated ~$100M negative FX impact vs prior guidance. - Pre-tax operating margin improvement now ~75 bps (vs earlier 50 bps), benefiting from operating efficiencies and expected tariff cost recoupment, while considering costs from the 53rd week and the U.S. agreement to improve patient access/lower costs. - Adjusted operational EPS raised to $11.50–$11.65; reported EPS $11.60–$11.75.
Innovative Medicine momentum (key opportunities driving confidence) - Q2 Innovative Medicine sales: $16.4B (+6.8%), despite ~760 bps STELARA headwind; management noted 96% of Innovative Medicine business excluding STELARA grew >14%. - Major growth highlights: - DARZALEX: >17.6% (share gains; strong frontline). - CARVYKTI: +47.7%; TECVAYLI: +56.1%; TALVEY: +62.6%. - RYBREVANT (+61.6%) via launch uptake and share gains. - TREMFYA (+71%) led by IBD; also received approval tied to structural damage inhibition in psoriasis/PsA. - SPRAVATO (+40%); CAPLYTA (+70.9%). - Launch progress: ICOTYDE in psoriasis—~11,000 patients initiated, >18,000 prescriptions, 6,000 unique prescribers (including >50% advanced practice professionals, ~40% dermatologists). ~50%+ commercial payer coverage within 90 days. - Longer-term “surprise but positive”: ICOTYDE uptake is strong and not slowing TREMFYA; co-positioning is clear (systemic oral first-choice vs biologic first-choice, especially with PsA overlap).

Exclusive for Stockcircle Pro members

Sign upSign Up
$268.17

Target Price by Analysts

6% upsideJohnson & Johnson Target Price DetailsTarget Price
$288.11

Current Fair Value

13.9% upside

Undervalued by 13.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$618.61 Billion
Enterprise Value$615.47 Billion
Dividend Yield$5.24 (2.04%)
Earnings per Share$11.03
Beta0.24
Outstanding Shares2,445,233,000

Return

Return on Equity25.92%ROE
Return on Assets10.47%
Return on Invested Capital17.50%

Valuation & Multiples

P/E Ratio29.64P/E Ratio
PEG-56.56PEG
Price to Sales8.73Price to Sales
Price to Book Ratio7.67Price to Book Ratio
Enterprise Value to Revenue8.48
Enterprise Value to EBIT24.57
Enterprise Value to Net Income29
Total Debt to Enterprise0.03
Debt to Equity0.23Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 15, 2026
EPS Estimate
$2.84
Average shareholder expectation
Revenue Estimate
$25.06 B
Average shareholder expectation

Next Earnings Call

Expected Date
October 13, 2026
EPS Estimate
$3.02
Average shareholder expectation
Revenue Estimate
$25.32 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 84.56%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.57%▼ 71.97%
Total Invested$3.54B▼ 99.18%
Investors Holding381▼ 4332.00%

ESG Score

No data

About Johnson & Johnson

CEO: Alex Gorsky

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today...

Relevant Senate Committees

Finance

This powerful committee controls taxation, trade policy, and entitlement spending (like Medicare and Medicaid pricing), all of which directly and profoundly impact JNJ's profitability, global market access, and revenue.

Appropriations

This committee directly allocates discretionary federal spending, including funding for health programs, medical research, and government procurement of healthcare products, directly impacting JNJ's revenue streams and market opportunities.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA and NIH, which are critical for drug approval, clinical trials, and research funding – all essential to JNJ's core pharmaceutical business.

Judiciary

This committee's oversight of antitrust laws is critical for a large company like JNJ, and its jurisdiction over intellectual property (patents) is fundamental to the pharmaceutical industry's business model.

Special Committee on Aging

Hearings on drug pricing and healthcare quality for older Americans directly impact JNJ's pharmaceutical revenue, public image, and potential for regulatory scrutiny.

Veterans' Affairs

JNJ provides healthcare products and potentially medical devices, making it a direct beneficiary or supplier to the Department of Veterans Affairs, whose funding decisions directly impact JNJ's government contracts.